Leo has been very clear that he won’t strike a deal until after phase2. He has been consistent in that for the past 3 years. B-OM will likely be the first Phase3 drug for IPIX following a successful end-of-Phase meeting with the FDA. That should then be followed with a deal for OM if not the entire OM/IBD Brilacidin platform.
Market Data 
Markets 
AI
